Left ventricular diastolic dysfunction worsens prognosis in patients with heart failure due to dilated cardiomyopathy.

IF 3.2 2区 医学 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS
Mateusz Winiarczyk, Ewa Dziewięcka, Sylwia Wiśniowska-Śmiałek, Agnieszka Stępień, Katarzyna Graczyk, Agata Leśniak-Sobelga, Marta Hlawaty, Jakub Woźniak, Maryia Savitskaya, Katarzyna Holcman, Magdalena Kostkiewicz, Piotr Podolec, Paweł Rubiś
{"title":"Left ventricular diastolic dysfunction worsens prognosis in patients with heart failure due to dilated cardiomyopathy.","authors":"Mateusz Winiarczyk, Ewa Dziewięcka, Sylwia Wiśniowska-Śmiałek, Agnieszka Stępień, Katarzyna Graczyk, Agata Leśniak-Sobelga, Marta Hlawaty, Jakub Woźniak, Maryia Savitskaya, Katarzyna Holcman, Magdalena Kostkiewicz, Piotr Podolec, Paweł Rubiś","doi":"10.1002/ehf2.15119","DOIUrl":null,"url":null,"abstract":"<p><strong>Aims: </strong>The prognostic significance of left ventricular (LV) diastolic dysfunction (LVDD) severity in patients with dilated cardiomyopathy (DCM) remains uncertain. This study aimed to evaluate the association of LVDD severity and elevated left atrial pressure (eLAP) with patient outcomes in stable, non-acutely decompensated patients with DCM.</p><p><strong>Methods: </strong>This single-centre, retrospective, observational study involved 740 DCM patients (either inpatients or outpatients) managed at our tertiary cardiac centre between 2010 and 2021. Due to incomplete data, 96 patients were excluded. LVDD and eLAP were assessed using echocardiography according to the 2016 guidelines of the European Association of Cardiovascular Imaging (EACVI). The primary outcomes were all-cause mortality and heart failure (HF)-related mortality.</p><p><strong>Results: </strong>The final cohort comprised of 644 DCM patients [mean age: 52 ± 12 years, LV ejection fraction (LVEF): 26 ± 10%]. Over a median follow-up period of 41 (18.5-66.7) months, 105 (16.3%) patients died: 8 (5.3%) patients in the normal left atrial pressure (nLAP) group and 97 (19.6%) patients in the eLAP group. eLAP was identified as an independent prognostic factor for both all-cause mortality [hazard ratio (HR) 2.0; 95% confidence interval (CI) 1.1-3.7; P = 0.01] and HF-related mortality (HR 2.5; 95% CI 1.01-6.5; P = 0.04), even after adjusting for LVEF and atrial fibrillation (AF) presence. Additionally, HF-related mortality rates were significantly higher in patients with moderate to severe LVDD compared with those with mild LVDD [5 (3.3%) vs. 67 (13.6%), P < 0.05].</p><p><strong>Conclusions: </strong>This study's findings highlight the importance of assessing the severity of LVDD in patients with DCM, which provides incremental prognostic information over LVEF.</p>","PeriodicalId":11864,"journal":{"name":"ESC Heart Failure","volume":" ","pages":""},"PeriodicalIF":3.2000,"publicationDate":"2024-11-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"ESC Heart Failure","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1002/ehf2.15119","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0

Abstract

Aims: The prognostic significance of left ventricular (LV) diastolic dysfunction (LVDD) severity in patients with dilated cardiomyopathy (DCM) remains uncertain. This study aimed to evaluate the association of LVDD severity and elevated left atrial pressure (eLAP) with patient outcomes in stable, non-acutely decompensated patients with DCM.

Methods: This single-centre, retrospective, observational study involved 740 DCM patients (either inpatients or outpatients) managed at our tertiary cardiac centre between 2010 and 2021. Due to incomplete data, 96 patients were excluded. LVDD and eLAP were assessed using echocardiography according to the 2016 guidelines of the European Association of Cardiovascular Imaging (EACVI). The primary outcomes were all-cause mortality and heart failure (HF)-related mortality.

Results: The final cohort comprised of 644 DCM patients [mean age: 52 ± 12 years, LV ejection fraction (LVEF): 26 ± 10%]. Over a median follow-up period of 41 (18.5-66.7) months, 105 (16.3%) patients died: 8 (5.3%) patients in the normal left atrial pressure (nLAP) group and 97 (19.6%) patients in the eLAP group. eLAP was identified as an independent prognostic factor for both all-cause mortality [hazard ratio (HR) 2.0; 95% confidence interval (CI) 1.1-3.7; P = 0.01] and HF-related mortality (HR 2.5; 95% CI 1.01-6.5; P = 0.04), even after adjusting for LVEF and atrial fibrillation (AF) presence. Additionally, HF-related mortality rates were significantly higher in patients with moderate to severe LVDD compared with those with mild LVDD [5 (3.3%) vs. 67 (13.6%), P < 0.05].

Conclusions: This study's findings highlight the importance of assessing the severity of LVDD in patients with DCM, which provides incremental prognostic information over LVEF.

左心室舒张功能障碍会加重扩张型心肌病导致的心力衰竭患者的预后。
目的:扩张型心肌病(DCM)患者左心室舒张功能障碍(LVDD)严重程度的预后意义仍不确定。本研究旨在评估左心室舒张功能障碍严重程度和左心房压力升高(eLAP)与病情稳定、非急性失代偿的 DCM 患者预后的关系:这项单中心、回顾性、观察性研究涉及 2010 年至 2021 年期间在我们三级心脏病中心接受治疗的 740 名 DCM 患者(住院或门诊患者)。由于数据不完整,有 96 名患者被排除在外。根据欧洲心血管成像协会(EACVI)2016 年指南,采用超声心动图评估 LVDD 和 eLAP。主要结果为全因死亡率和心力衰竭(HF)相关死亡率:最终队列由 644 名 DCM 患者组成[平均年龄:52 ± 12 岁,左心室射血分数(LVEF):26 ± 10%]。在41(18.5-66.7)个月的中位随访期内,105(16.3%)名患者死亡:正常左心房压(nLAP)组8(5.3%)名,eLAP组97(19.6%)名。eLAP 被确定为全因死亡率[危险比 (HR) 2.0; 95% 置信区间 (CI) 1.1-3.7; P = 0.01]和 HF 相关死亡率(HR 2.5; 95% CI 1.01-6.5; P = 0.04)的独立预后因素,即使在调整 LVEF 和心房颤动 (AF) 存在后也是如此。此外,与轻度 LVDD 患者相比,中重度 LVDD 患者的 HF 相关死亡率明显更高[5 (3.3%) vs. 67 (13.6%),P 结论:这项研究的结果凸显了评估 DCM 患者 LVDD 严重程度的重要性,它提供了比 LVEF 更多的预后信息。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
ESC Heart Failure
ESC Heart Failure Medicine-Cardiology and Cardiovascular Medicine
CiteScore
7.00
自引率
7.90%
发文量
461
审稿时长
12 weeks
期刊介绍: ESC Heart Failure is the open access journal of the Heart Failure Association of the European Society of Cardiology dedicated to the advancement of knowledge in the field of heart failure. The journal aims to improve the understanding, prevention, investigation and treatment of heart failure. Molecular and cellular biology, pathology, physiology, electrophysiology, pharmacology, as well as the clinical, social and population sciences all form part of the discipline that is heart failure. Accordingly, submission of manuscripts on basic, translational, clinical and population sciences is invited. Original contributions on nursing, care of the elderly, primary care, health economics and other specialist fields related to heart failure are also welcome, as are case reports that highlight interesting aspects of heart failure care and treatment.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信